CRCM LP’s Atrium Therapeutics RNA Stock Holding History

CRCM LP’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-641,539	Closed	-$8.63M	–	23
2026 Q2	$8.63M	Buy	+641,539	New	+$8.38M	5.67%	3

Other funds holding RNA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Arbiter Partners Capital Management New York $235M AUM 94.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Groupe la Francaise Paris, France $8.63B AUM 33.07% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

CRCM LP's RNA Position: Q3 2026 in Review

CRCM LP sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 641,539 shares — an estimated $8.63M sold.

CRCM LP first reported a position in RNA in Q2 2026 and held it in 1 quarter. The position peaked at $8.63M in Q2 2026. 65 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

CRCM LP reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
CRCM LP sold 641,539 Atrium Therapeutics shares in Q3 2026, an estimated $8.63M.
CRCM LP first reported a position in Atrium Therapeutics in Q2 2026 and held it in 1 quarter.
CRCM LP's Atrium Therapeutics position peaked at $8.63M in Q2 2026.
65 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on CRCM LP's 13F filing for Q3 2026, filed 12 Nov 2026.